{"drugs":["Cefotaxime Sodium","Claforan"],"mono":{"0":{"id":"111730-s-0","title":"Generic Names","mono":"Cefotaxime Sodium"},"1":{"id":"111730-s-1","title":"Dosing and Indications","sub":[{"id":"111730-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bacterial meningitis:<\/b> 8 to 12 g\/day IV divided every 4 to 6 hours (guideline dosing)<\/li><li><b>Bacterial septicemia:<\/b> 2 g IV every 6 to 8 hours, up to 2 grams every 4 hours<\/li><li><b>Cesarean section - Postoperative infection; Prophylaxis:<\/b> 1 g IV as soon as umbilical cord is clamped, then 1 g IV\/IM at 6 and 12 hours after the first dose for a total of 3 doses<\/li><li><b>Gonorrhea:<\/b> uncomplicated, 500 mg IM as a single dose plus either a single dose of azithromycin 1 g ORALLY or doxycycline 100 mg ORALLY twice daily for 7 days (guideline dosing)<\/li><li><b>Gonorrhea:<\/b> disseminated (alternative to ceftriaxone), 1 g IV every 8 hours for 24 to 48 hours after improvement begins then switch to appropriate oral therapy to complete at least 1 week of therapy (guideline dosing)<\/li><li><b>Gonorrhea:<\/b> cervical\/urethral and rectal, 0.5 to 1 g IM as a single dose (manufacturer dosing)<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours<\/li><li><b>Infectious disease of abdomen:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours<\/li><li><b>Lower respiratory tract infection:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours<\/li><li><b>Lyme disease:<\/b> 2 g IV three times daily for 14 days (range, 10 to 28 days) for early Lyme disease with acute neurological disease manifested by meningitis or radiculopathy, or patients with seventh-cranial-nerve palsy with CNS involvement; for 14 to 21 days for the initial treatment of hospitalized patients with Lyme carditis; for 14 to 28 days for Lyme arthritis with neurological involvement, including those refractory to oral therapy, or late neurologic Lyme disease<\/li><li><b>Pelvic inflammatory disease:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours; consider adding doxycycline 100 mg ORALLY twice daily for 14 days with or without metronidazole 500 mg ORALLY twice daily for 14 days<\/li><li><b>Postoperative infection; Prophylaxis:<\/b> 1 g IV\/IM 30 to 90 minutes prior to the start of surgery<\/li><li><b>Urinary tract infectious disease:<\/b> uncomplicated infections, 1 g IV\/IM every 12 hours; moderate to severe infections, 1 to 2 g IV\/IM every 8 hours, up to 2 g IV every 4 to 6 hours<\/li><\/ul>"},{"id":"111730-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bacterial meningitis:<\/b> age 0 to 7 days, 100 to 150 mg\/kg\/day IV divided every 8 to 12 hours; age 8 to 28 days, 150 to 200 mg\/kg\/day IV divided every 6 to 8 hours; infants and children, 225 to 300 mg\/kg\/day divided every 6 to 8 hours (guideline dosing)<\/li><li><b>Bacterial septicemia:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 week and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Bacterial septicemia:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><li><b>Gonorrhea:<\/b> disseminated and scalp abscesses (newborns), 25 mg\/kg IV\/IM every 12 hours for 7 days; treat 10 to 14 days for meningitis<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 wk and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 week and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><li><b>Infectious disease of abdomen:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 week and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Infectious disease of abdomen:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><li><b>Lower respiratory tract infection:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 week and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Lower respiratory tract infection:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><li><b>Lower respiratory tract infection:<\/b> (community acquired pneumonia; older than 3 months of age) 150 mg\/kg\/day IV divided every 8 hours (guideline dosing)<\/li><li><b>Lyme disease:<\/b> 150 to 200 mg\/kg\/day IV divided into 3 or 4 doses for 14 days (range, 10 to 28 days) for early Lyme disease with acute neurological disease manifested by meningitis or radiculopathy, or patients with seventh-cranial-nerve palsy with CNS involvement; for 14 to 21 days for the initial treatment of hospitalized patients with Lyme carditis; for 14 to 28 days for Lyme arthritis with neurological involvement, including those refractory to oral therapy, or late neurologic Lyme disease; maximum daily dose, 6 g<\/li><li><b>Urinary tract infectious disease:<\/b> neonates (0 to 4 weeks, less than 1200 g) 50 mg\/kg IV every 12 hours; (less than 1 week, 1200 to 2000 g) 50 mg\/kg IV every 12 hours; (less than 1 week, greater than 2000 g) 50 mg\/kg IV every 8 to 12 hours; (1 week and older, 1200 to 2000 g) 50 mg\/kg IV every 8 hours; (1 week and older, greater than 2000 g) 50 mg\/kg IV every 6 to 8 hours<\/li><li><b>Urinary tract infectious disease:<\/b> infants and children (1 month and older) mild to moderate infection, 75 to 100 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 4 to 6 g\/day; severe infection, 150 to 200 mg\/kg\/day IV\/IM in 3 or 4 divided doses, MAX 8 to 10 g\/day<\/li><\/ul>"},{"id":"111730-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> estimated CrCl less than 20 mL\/min\/1.73 m(2), reduce dose by 50% "},{"id":"111730-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bacterial meningitis<\/li><li>Bacterial septicemia<\/li><li>Cesarean section - Postoperative infection; Prophylaxis<\/li><li>Gonorrhea<\/li><li>Infection of bone - Infectious disorder of joint<\/li><li>Infection of skin AND\/OR subcutaneous tissue<\/li><li>Infectious disease of abdomen<\/li><li>Lower respiratory tract infection<\/li><li>Pelvic inflammatory disease<\/li><li>Postoperative infection; Prophylaxis<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bacterial endocarditis<\/li><li>Lyme disease<\/li><li>Salmonella infection<\/li><\/ul>"}]},"3":{"id":"111730-s-3","title":"Contraindications\/Warnings","sub":[{"id":"111730-s-3-9","title":"Contraindications","mono":"Hypersensitivity to cefotaxime sodium or to any cephalosporin <br\/>"},{"id":"111730-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- Extravasation, including extensive perivascular, may occur causing tissue damage requiring surgical intervention; proper administration and monitoring recommended<\/li><li>Gastrointestinal:<\/li><li>--History of gastrointestinal disease, especially colitis<\/li><li>-- Clostridium difficile-associated diarrhea, ranging from mild diarrhea to fatal colitis, has been reported<\/li><li>Hematologic:<\/li><li>-- Leukopenia, neutropenia, or granulocytopenia and in rare cases bone marrow failure, pancytopenia, or agranulocytosis may occur; monitoring recommended for therapy lasting longer than 10 days<\/li><li>Immunologic:<\/li><li>-- Previous hypersensitivity to penicillins, other drugs, or other demonstrated allergy; increased risk of allergic reaction including serious reactions requiring medical intervention<\/li><li>Renal:<\/li><li>-- Renal insufficiency; dose reduction recommended<\/li><li>Other:<\/li><li>-- Coombs' test; may induce a positive result<\/li><li>-- Rapid bolus injection via a central venous catheter has resulted in life-threatening arrhythmias; use proper administration<\/li><li>-- Urine glucose tests utilizing copper reduction (Benedict's or Fehling's solutions, Clinitest(R) tablets); may induce a false positive reaction<\/li><\/ul>"},{"id":"111730-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Cefotaxime: B (FDA)<\/li><li>Cefotaxime: B1 (AUS)<\/li><\/ul>"},{"id":"111730-s-3-12","title":"Breast Feeding","mono":"<ul><li>Cefotaxime: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Cefotaxime: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"111730-s-4","title":"Drug Interactions","sub":{"1":{"id":"111730-s-4-14","title":"Major","mono":"<ul>Warfarin (probable)<\/ul>"},"2":{"id":"111730-s-4-15","title":"Moderate","mono":"<ul>Probenecid (probable)<\/ul>"}}},"5":{"id":"111730-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain, Injection site phlebitis, Rash (2.2%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Vomiting<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Agranulocytosis (Less than 1%), Granulocytopenic disorder, Leukopenia (Less than 1%), Neutropenic disorder (Less than 1%), Pancytopenia<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (2.4%)<\/li><\/ul>"},"6":{"id":"111730-s-6","title":"Drug Name Info","sub":{"0":{"id":"111730-s-6-17","title":"US Trade Names","mono":"Claforan<br\/>"},"2":{"id":"111730-s-6-19","title":"Class","mono":"<ul><li>3rd Generation Cephalosporin<\/li><li>Antibiotic<\/li><\/ul>"},"3":{"id":"111730-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"111730-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"111730-s-7","title":"Mechanism Of Action","mono":"Cefotaxime sodium, a semisynthetic, broad spectrum cephalosporin, exhibits its bactericidal activity by inhibiting cell wall synthesis in a wide range of gram-positive and gram-negative microorganisms.<br\/>"},"8":{"id":"111730-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"111730-s-8-23","title":"Absorption","mono":"Intramuscular: time to peak concentration, within 30 min <br\/>"},"2":{"id":"111730-s-8-25","title":"Metabolism","mono":"Metabolites: desacetyl derivative (major metabolite), M(2) and M(3) <br\/>"},"3":{"id":"111730-s-8-26","title":"Excretion","mono":"Renal: (intravenous), about 60%, 15% to 25% as desacetyl derivative, approximately 20% to 36% unchanged <br\/>"},"4":{"id":"111730-s-8-27","title":"Elimination Half Life","mono":"<ul><li>approximately 1 h<\/li><li>Infants: 3.4 h to 4.6 h<\/li><\/ul>"}}},"9":{"id":"111730-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/>reconstitute 500 mg, 1 g, and 2 g vials with 2, 3, and 5 mL Sterile Water for Injection or Bacteriostatic Water for Injection for concentrations of 230, 300, and 330 mg\/mL, respectively<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute 500 mg, 1 g, and 2 g vials with 10 mL Sterile Water for Injection for concentrations of 50, 95, and 180 mg\/mL, respectively<\/li><li>adult: (intermittent infusion) 1 g or 2 g in 10 mL of sterile water for injection may be injected directly over 3 to 5 minutes, or may be given through the tubing of an existing IV; advisable to discontinue administration of other solutions at the same site<\/li><li>reconstituted solutions of 500 mg and 1 g vials must be administered within 24 hours if stored below 22 degrees C, within 7 days under refrigeration, and within 5 days in plastic syringes<\/li><li>reconstituted 2 g vials must be administered within 12 hours if stored below 22 degrees C, 7 days under refrigeration, and within 5 days in plastic syringes<\/li><li>reconstituted 1 g and 2 g infusion bottles must be administered within 24 hours if stored below 22 degrees C, within 10 days under refrigeration<\/li><li>continuous infusion of higher doses; solution may be further diluted to up to 1000 mL of compatible solution and use within 24 hours if stored below 22 degrees C, or within 5 days under refrigeration<\/li><li>pediatric: (intermittent infusion) dilute to final concentration of 10 to 50 mg\/mL in D5W or NS and administer over 15 to 30 minutes<\/li><li>pediatric: (IV push) dilute to concentration of 50 mg\/mL and administer over 3 to 5 minutes<\/li><li>pediatric: maximum concentrations for peripheral administration are 86 mg\/mL in D5W, 73 mg\/mL in NS, and 147 mg\/mL in sterile water for injection<\/li><\/ul><\/li><\/ul>"},"10":{"id":"111730-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>CBC for treatment courses longer than 10 days include differential<\/li><li>renal function; elderly<\/li><li>signs and symptoms of superinfection<\/li><\/ul>"},"11":{"id":"111730-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 10 GM, 500 MG<br\/><\/li><li><b>Amerinet Claforan<\/b><br\/>Injection Powder for Solution: 1 GM<br\/><\/li><li><b>Claforan<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 10 GM, 500 MG<br\/><\/li><li><b>Novaplus Claforan<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 10 GM<br\/><\/li><\/ul>"},"12":{"id":"111730-s-12","title":"Toxicology","sub":[{"id":"111730-s-12-31","title":"Clinical Effects","mono":"<b>CEPHALOSPORINS<\/b><br\/>OVERDOSE: Acute ingestion of large doses of cephalosporins may result in nausea, vomiting, diarrhea, and abdominal pain. Seizures have developed after parenteral overdose. ADVERSE EFFECTS: COMMON: Hypersensitivity reactions, including anaphylaxis, may commonly occur with therapy; oral exposures are less likely to cause severe allergic reactions than parenteral exposures. Seizures have also been reported following therapeutic administration. Prolonged prothrombin times, thrombocytopenia, and coagulopathies associated with a qualitative platelet defect and aggregation abnormalities have been reported following IV cephalosporin therapy. Pseudocholelithiasis may follow intravenous administration of ceftriaxone. Several cases of fatal hemolytic reactions following intravenous ceftriaxone therapy have been reported in children with serious hematologic abnormalities.<br\/>"},{"id":"111730-s-12-32","title":"Treatment","mono":"<b>CEPHALOSPORINS <\/b><br\/><ul><li>Decontamination: Generally not indicated in patients with no underlying health problems. Activated charcoal may be necessary for patients with underlying renal insufficiency.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor renal function, electrolytes, CBC including platelets.<\/li><li>Anaphylaxis: Mild to moderate allergic reactions may be treated with antihistamines with or without inhaled beta adrenergic agonists, corticosteroids or epinephrine. Diphenhydramine: ADULTS: 50 mg orally, IV, or IM initially, then 25 to 50 mg orally every 4 to 6 hours for 24 to 72 hours. CHILDREN: 1.25 mg\/kg orally, IV, or IM initially, then 5 mg\/kg\/day orally in 4 divided doses for 24 to 72 hours. Treatment of severe anaphylaxis also includes oxygen supplementation, aggressive airway management, epinephrine, ECG monitoring, and IV fluids.<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Blood coagulation disorder: Vitamin K, fresh frozen plasma<\/li><li>Intrathecal injection: Treat seizures with anticonvulsants (benzodiazepines, propofol, phenobarbital); endotracheal intubation and mechanical ventilation as needed. Keep the patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults. Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers). For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or lactated ringers through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr). Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><\/ul>"},{"id":"111730-s-12-33","title":"Range of Toxicity","mono":"<b>CEPHALOSPORINS<\/b><br\/>TOXICITY: Serious toxicity is unlikely following large oral doses of cephalosporins. Crystalluria and hematuria has been described in a 3-year-old boy who ingested 104 mg\/kg of cephalexin. THERAPEUTIC DOSE: Varies with agent. CEPHALEXIN: CHILDREN:  25 to 100 milligrams\/kilogram\/24 hours orally, up to a maximum of 4 grams\/day, divided every 6 hours. <br\/>"}]},"13":{"id":"111730-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, or fever.<\/li><li>Instruct patient to report signs\/symptoms serum-sickness-like reactions (rash, urticaria, arthralgia, fever, malaise, enlarged lymph nodes).<\/li><li>Advise patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine. Other superinfection signs\/symptoms should be reported as well.<\/li><\/ul>"}}}